ConductScience.org, home

Paper42959554PubMed

Vedolizumab use for severe chronic enterocolitis in a child with Hoyeraal-Hreidarsson syndrome: A case report.

Chiba Y and 6 others. JPGN Rep, 2026.

Cite this record

ConductScience Library. Vedolizumab use for severe chronic enterocolitis in a child with Hoyeraal-Hreidarsson syndrome: A case report. Papers, record 42959554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42959554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vedolizumab use for severe chronic enterocolitis in a child with Hoyeraal-Hreidarsson syndrome: A case report.
Journal
JPGN Rep
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-31

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chiba YYasutaka
2Takahashi MManabuhttps://orcid.org/0000-0003-0908-9227
3Yoshida TTaro
4Tagane SSeiya
5Shiohata TTakeshi
6Miura SShoko
7Akasaka MManami

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References8

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127128385Novel Compound Heterozygous RTEL1 Gene Mutations in a Patient With Hoyeraal-Hreidarsson Syndrome.Pediatr Blood Cancer2016https://conductscience.org/library/papers/27128385PubMed
222078571Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita.J Allergy Clin Immunol2012https://conductscience.org/library/papers/22078571PubMed
336776130Neonatal intestinal obstruction in Hoyeraal-Hreidarsson syndrome with novel RTEL1 variants.Pediatr Blood Cancer2023https://conductscience.org/library/papers/36776130PubMed
440718704A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights.Ther Adv Gastroenterol2025https://conductscience.org/library/papers/40718704PubMed
534279480Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.J Clin Med2021https://conductscience.org/library/papers/34279480PubMed
631478401An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.Expert Rev Hematol2019https://conductscience.org/library/papers/31478401PubMed
723329068Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita.Hum Genet2013https://conductscience.org/library/papers/23329068PubMed
832710398An RTEL1 Mutation Links to Infantile-Onset Ulcerative Colitis and Severe Immunodeficiency.J Clin Immunol2020https://conductscience.org/library/papers/32710398PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42959554

GET https://conductscience.org/api/papers/v1/42959554/authors